138 related articles for article (PubMed ID: 36641487)
21. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
[TBL] [Abstract][Full Text] [Related]
22. Redox-Sensitive and Hyaluronic Acid-Functionalized Nanoparticles for Improving Breast Cancer Treatment by Cytoplasmic 17α-Methyltestosterone Delivery.
Rezaei S; Kashanian S; Bahrami Y; Cruz LJ; Motiei M
Molecules; 2020 Mar; 25(5):. PubMed ID: 32151062
[TBL] [Abstract][Full Text] [Related]
23. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
[TBL] [Abstract][Full Text] [Related]
24. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors.
Yang X; Wang Y; Chen S; Zhang S; Cui C
Int J Nanomedicine; 2021; 16():7051-7069. PubMed ID: 34703227
[TBL] [Abstract][Full Text] [Related]
26. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
27. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
28. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
[TBL] [Abstract][Full Text] [Related]
29. ATRP Fabricated and Short Chain Polyethylenimine Grafted Redox Sensitive Polymeric Nanoparticles for Codelivery of Anticancer Drug and siRNA in Cancer Therapy.
Nehate C; Moothedathu Raynold AA; Koul V
ACS Appl Mater Interfaces; 2017 Nov; 9(45):39672-39687. PubMed ID: 29048878
[TBL] [Abstract][Full Text] [Related]
30. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
[TBL] [Abstract][Full Text] [Related]
31. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
32. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
[TBL] [Abstract][Full Text] [Related]
33. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
34. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
[TBL] [Abstract][Full Text] [Related]
35. Electrostatic Attractive Self-Delivery of siRNA and Light-Induced Self-Escape for Synergistic Gene Therapy.
Yang Y; Ning H; Xia T; Du J; Sun W; Fan J; Peng X
Adv Mater; 2023 Jul; 35(30):e2301409. PubMed ID: 37084041
[TBL] [Abstract][Full Text] [Related]
36. Bioreducible Cross-Linked Hyaluronic Acid/Calcium Phosphate Hybrid Nanoparticles for Specific Delivery of siRNA in Melanoma Tumor Therapy.
Zhou Z; Li H; Wang K; Guo Q; Li C; Jiang H; Hu Y; Oupicky D; Sun M
ACS Appl Mater Interfaces; 2017 May; 9(17):14576-14589. PubMed ID: 28393529
[TBL] [Abstract][Full Text] [Related]
37. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
Choi KM; Jang M; Kim JH; Ahn HJ
Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
[TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
[TBL] [Abstract][Full Text] [Related]
39. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells.
Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L
Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
